GLP-1 & compounded medication availability in Tennessee (2026)
Tennessee sits in the quiet middle of the national compounding map. Its pharmacy regulators have published nothing that singles out GLP-1s or peptide lines, so what decides a Memphis or Nashville order is the plumbing: whether the pharmacy holds the right Tennessee credential, whether the prescriber is licensed here, and whether the prescription was written for you specifically. All of that is checkable, and this page cites where.
What ships to Tennessee: all ten lines
| Product line | Available in Tennessee? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Ships from licensed partner pharmacies credentialed for Tennessee. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same flat national price at every dose, Tennessee included. |
| NAD+ | Yes | 8–10 business days | Ordered through the same telehealth flow as the GLP-1 lines. |
| Sermorelin | Yes | 8–10 business days | No Tennessee-specific condition attaches to this line. |
| Glutathione | No | N/A | Not in the OrderlyMeds formulary at the moment. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; its federal record is stated below. |
| TB-500 | Yes | 8–10 business days | Injectable line. The section below carries the federal detail. |
| KPV | No | N/A | Not carried anywhere, since our peptide formulary is injectable-only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; see its own federal section further down. |
| MOTS-c | Yes | 8–10 business days | Injectable line whose federal history is its own, set out below. |
An honest No beats a padded catalog, so a No above means exactly that. Tennessee rows were last checked on November 16, 2026.
Research peptides in Tennessee: BPC-157, TB-500, KPV, Epitalon & MOTS-c
OrderlyMeds carries four of these five lines for Tennessee addresses: BPC-157, TB-500, Epitalon and MOTS-c, each compounded as an injectable and filled on a patient-specific prescription. KPV is the exception: we compound these lines as injectables only, and KPV is not one of them. Each section below states that line’s own federal record, and states it whether or not the line ships to you, because an availability question about these peptides deserves a sourced answer.
BPC-157 in Tennessee
Ships to Tennessee addresses as a compounded injectable on a patient-specific prescription. Both federal facts below apply in full.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Tennessee
Available to Tennessee patients as a compounded injectable, patient-specific prescription required. Its federal record follows.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Tennessee
Not shipped to Tennessee or any other state. Our peptide formulary is injectable-only, and KPV is not compounded that way for us.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Tennessee
In the Tennessee formulary as a compounded injectable, on a patient-specific prescription. The federal facts below are unchanged by geography.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Tennessee
Ships to Tennessee as a compounded injectable, patient-specific prescription required. Its federal record is its own, so read it below rather than the sections above.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Tennessee’s pharmacy regulators say about compounded medications
Tennessee takes a credential-first posture. The state has published no position singling out compounded GLP-1s or peptides, which leaves three structural questions carrying all the weight for a telehealth order: who may ship into the state, who may prescribe, and what the prescription has to be. Each answer below is cited to the regulator itself.
No out-of-state pharmacy practice site may conduct business in Tennessee until it obtains the required license from the Tennessee Board of Pharmacy, and a nonresident pharmacy’s designated pharmacist-in-charge must hold a current Tennessee pharmacist license. Source: Tennessee Board of Pharmacy.
The Tennessee Board of Pharmacy regulates compounding through its general practice and licensure rules and has published no guidance specific to GLP-1 medications or peptide compounding. Source: Tennessee Board of Pharmacy.
Tennessee permits prescriptions issued on the basis of a telemedicine encounter meeting the applicable standard of care; a prior in-person visit is not required for the medication lines on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.
In practice a Tennessee order runs the standard OrderlyMeds path: an online eligibility check, an evaluation by a Tennessee-licensed provider, and fulfillment by a licensed partner pharmacy holding the state credential above. Pricing is national, so the number on our pricing page is the Tennessee number.
Tennessee availability FAQs
Is compounded semaglutide available in Tennessee?
Yes. It ships to Tennessee addresses from licensed partner pharmacies, starting at $74/month for the first two months for new customers.
Can I complete the whole process from home in Tennessee?
Yes. The evaluation happens by telemedicine with a Tennessee-licensed provider, and the medication arrives by carrier. The regulator section above cites the detail.
Which research peptides ship to Tennessee?
BPC-157, TB-500, Epitalon and MOTS-c, as compounded injectables on a patient-specific prescription. KPV is not carried. The sections above state each line’s own federal record.
How long does delivery to Tennessee take?
Our published window is 8–10 business days from signup.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
